Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome

Sponsor
Liposome (Industry)
Overall Status
Completed
CT.gov ID
NCT00002019
Collaborator
(none)
19

Study Details

Study Description

Brief Summary

To evaluate the safety, tolerance and efficacy of three different dosage regimens of Amphotericin B Lipid Complex (ABLC) compared to Fungizone (Amphotericin B) in patients with AIDS and cryptococcal meningitis.

Condition or Disease Intervention/Treatment Phase
  • Drug: Amphotericin B, Lipid-based
  • Drug: Amphotericin B
N/A

Study Design

Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 0 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria

    Concurrent Medication:
    Allowed:
    • Intravenous pentamidine for treatment of Pneumocystis carinii pneumonia (PCP) but not for prophylaxis.
    Patients must have the following:
    • Meet the CDC criteria for diagnosis of AIDS.

    • Confirmed episode of acute cryptococcal meningitis.

    • Informed consent of the patient or guardian prior to entry.

    Exclusion Criteria

    Co-existing Condition:
    Patients with the following conditions or symptoms are excluded:
    • Clinical evidence of acute or chronic meningitis due to an agent other than Cryptococcus neoformans.

    • History of hypersensitivity/anaphylactoid reaction attributed to amphotericin B.

    • Any other concomitant condition which, in the opinion of the investigator, would preclude a patient's participation in the study.

    Concurrent Medication:
    Excluded:
    • Corticosteroids.

    • Salicylates or other drugs known to interfere with prostaglandin synthesis except as specified in protocol.

    • Zidovudine.

    • Investigational agents.

    • Interferon.

    • Interleukin-2 (IL-2).

    • Steroids.

    • Isoprinosine.

    • Intrathecal Amphotericin B.

    • Intravenous Pentamidine PCP prophylaxis (only treatment).

    Patients with the following are excluded:
    • Clinical evidence of acute or chronic meningitis due to an agent other than Cryptococcus neoformans.

    • History of hypersensitivity/anaphylactoid reaction attributed to amphotericin B.

    • Inability to obtain appropriate follow-up visits.

    • Any other concomitant condition which, in the opinion of the investigator, would preclude a patient's participation in the study.

    Prior Medication:
    Excluded within 4 weeks of study entry:
    • Amphotericin B.

    • Excluded within 2 weeks of study entry:

    • Any other experimental drug.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Harbor - UCLA Med Ctr Torrance California United States 90502
    2 Dr Thomas Patterson New Haven Connecticut United States 06510
    3 Walter Reed Army Med Ctr Washington District of Columbia United States 203075001
    4 Rush Presbyterian - Saint Luke's Med Ctr Chicago Illinois United States 60612
    5 Natl Naval Med Ctr Bethesda Maryland United States 20889
    6 Univ Hosp Boston Massachusetts United States 02118
    7 East Orange Veterans Administration Med Ctr East Orange New Jersey United States 07018
    8 Saint Michael's Med Ctr Newark New Jersey United States 07102
    9 Beth Israel Med Ctr / Peter Krueger Clinic New York New York United States 10003
    10 Dr Dorothy Friedberg New York New York United States 10016
    11 New York Univ Med Ctr New York New York United States 10016
    12 Cornell Univ Med College New York New York United States 10021
    13 Saint Luke's - Roosevelt Hosp Ctr New York New York United States 10025
    14 Mount Sinai Med Ctr / Jack Martin Fund Clinic New York New York United States 10029
    15 Mount Sinai Med Ctr New York New York United States 10029
    16 Buckley Braffman Stern Med Associates Philadelphia Pennsylvania United States 19107
    17 Univ TX Galveston Med Branch Galveston Texas United States 77550
    18 Audie L Murphy Veterans Administration Hosp San Antonio Texas United States 78284
    19 Univ of Utah School of Medicine Salt Lake City Utah United States 84132

    Sponsors and Collaborators

    • Liposome

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00002019
    Other Study ID Numbers:
    • 051A
    First Posted:
    Aug 31, 2001
    Last Update Posted:
    Jun 24, 2005
    Last Verified:
    Nov 1, 1999

    Study Results

    No Results Posted as of Jun 24, 2005